

Annual Report 2018





Table of Contents

MESSAGE FROM THE PRESIDENT	3
HIGHLIGHTS OF 2018	5
ECL Executive Board General Assembly and Conference	5
Patient Support Working Group	9
Access To Medicines Task Force	10
MEPs Against Cancer	11
Tobacco Control Activities	12
Cancer Prevention	13
THE ECL SECRETARIAT	15
ECL MEMBERS	17
FINANCIAL REPORT	20
MEMBERSHIP OVERVIEW FOR 2018	24



MESSAGE FROM THE PRESIDENT

The ECL has established its status as one of the major players in cancer control in Europe. ECL's active engagement in cancer control enjoys respect from the European Commission, members of the European Parliament and other European organisations. ECL is a popular partner in international collaborations. The year 2018 was busy and productive for ECL and its members. It gives me great pleasure to report on our joint achievements.

We have now 26 member leagues in 23 countries. Several national leagues have expressed their interest in ECL and we hope to have an even larger membership in 2019.

The year 2018 started with an uncertainty whether and when the Operation Grant from the European Commission would come through. The delay was due to the complaints related to the European Commission's earlier decisions on Operation Grants. It took almost six months before the Grant was confirmed. We succeeded in using the time for preparing the forthcoming EC-funded activities and concentrating on other activities in the Spring.

The General Assembly which met in November 2018 in Berlin decided on the new Strategy for 2019–2021. ECL has six strategic goals: 1) Influence Cancer Control Policies, 2) Promote Cancer Prevention, 3) Enhance Access to Cancer Screening and Early Diagnosis, 4) Endure Equal Access to High Value Cancer Treatments for all Cancer Patients in Europe, 5) Develop Actions Supporting Cancer Patients, Survivors and Caregivers, 6) Grow Membership and Increase Impact of ECL in Europe.

ECL has influenced Cancer Control Policies in several ways. It has held regular meetings with MEPs, European Commission, Health Attachés, other European cancer organisations and other stakeholders. The ECL's Strategic mission was further crystallized in the EU Elections Manifesto "Beating



Cancer – Mission Possible", which was prepared in 2018 and publicized in the beginning of 2019. ECL is active in EU Joint Actions and is a subcontractor in two: the Joint Action on Innovative Partnership Action Against Cancer (www.ipaac.eu), in the Work Package on Cancer Prevention led by Finland, and in the Joint Action on Vaccinations which is being led by France (<https://eu-jav.com/>). ECL is also a partner in two EU-funded projects and a member of several EU Platforms.

The MEPs Against Cancer (MAC) group was again very active in 2018 and keeping the ECL Secretariat busy in a very positive way. This group aims to raise awareness of cancer at the political level, focusing on the many dimensions of cancer: prevention and promotion of health, protection of citizens from risks and cancer survivorship, among others. MEPs and the ECL Secretariat arranged altogether ten MAC Roundtables covering important topics

MESSAGE FROM THE PRESIDENT

related to cancer prevention and cancer care. We look forward to working with new Members of European Parliament after 2019 elections.

ECL continues to work on the dissemination of the European Code against Cancer. This activity is possible through co-financing by the Operating Grant of the European Commission. In 2018, ECL benefited from the first year grant of the European Commission's four-year Operating Grant, which ECL is receiving now for the second time. I would also like to thank Garnier International for its unrestricted grant, especially for our work to prevent skin cancers.

The Task Force for Access to Medicines was very active and productive in 2018. It continued its systematic work to increase equity in cancer care. There are still inequities between European countries in access to cancer medication. Furthermore, in many countries there are major delays before cancer patients get the best available treatment. In October, the ECL launched the "Let's talk Access" White Paper at the European Parliament. The White Paper is a major achievement itself, but its main purpose is to guide the European cancer organisations in their battle for equal and timely access cancer medicines.

The Patient Support Working Group (PSWG) is in the core of the ECL's mission. All cancer leagues aim to guarantee best possible care and support for cancer patients. The PSWG is a forum for sharing best practices and creating joint initiatives on topics such as access to insurance and financial

services, return to work, caregiver support, cancer rehabilitation and palliative care. PSWG members develop guidelines and other information sources to raise awareness and improve quality of care, and seek to empower the patient voice in national and European policy-making.

I would like to thank all working group and task force chairs and members for their superb work with true impact in 2018.

In November 2018, the German Cancer Society hosted the ECL meetings and Annual Conference in Berlin. These events were professionally organised and the host succeeded in creating an excellent environment for discussion between the member leagues. All ECL members and guests enjoyed inspiring lectures, productive meetings and a relaxing social programme. ECL organised a CEO Roundtable for the very first time, and it was a great success.

I would like to extend my warmest thanks to our member leagues, the committed and hard-working Board Members and to the proactive and professional Secretariat. Our impact on cancer control in Europe and our good reputation are very much based on the strong national influence of the leagues, the excellent work our staff is doing and the Board Members representing ECL in various important events.

Sakari Karjalainen
ECL President





HIGHLIGHTS OF 2018

ECL Executive Board

The 2018 Executive Board comprised of the following members:



Sakari Karjalainen - President
Cancer Society of Finland



Rui Medeiros - Vice President
Portuguese League against Cancer



Roisin Foster - Treasurer
Cancer Focus Northern Ireland



Jacqueline Godet
French Cancer League



Elizabeth Hjorth
Danish Cancer Society



Nicolas Philippou, Cyprus Assoc.
of Cancer Patients and Friends

HIGHLIGHTS OF 2018

ECL Executive Board

The ECL statutes and by-laws stipulate that the Board should meet at least four times a year. The ECL Executive Board met 4 times in 2018: in Brussels in February, in Porto in June, in Vienna in September (next to the ECCO summit) and in Berlin in November (next to the ECL General Assembly). In addition to the meetings and teleconferences, there are regular email correspondences and meetings at cancer conferences and events between the Board members, especially the President, Vice-President and Treasurer, and the Secretariat.

Notable agenda items for Board meetings this year included the monitoring of activities being implemented and deliverables of the EU Operating Grant, especially in relation to the dissemination of the European Code Against Cancer; the development

of the new ECL Strategy 2019-2021; the preparation and organization of the Annual Meetings in Berlin; membership recruitment and relationships with external partners (European Society of Radiology, European Cancer Organisation, European Cancer Concord, etc).

Overall, the Board is responsible for ECL's strategy, directions and main activities, organisational development, communications and relationship with members and other relevant organisations.

Board members are volunteers. ECL is grateful for their dedication and active contributions to the work of ECL throughout the year, as well as for their timely advice in guiding the ECL Secretariat in its activities.





ECL Annual Meetings

Berlin, Germany, November 2018

Annual Conference

10:00 - 10:15	WELCOME Olaf Ortmann, President, German Cancer Society Sakari Karjalainen, President, Association of European Cancer Leagues
10:15 - 12:30	Session 1: Developing Quality in Cancer Care Chair: Rui Medeiros Structural Aspects at the National Level Johannes Bruns, Secretary General, German Cancer Society (presentation 30 mins, Q&A 15 mins) Research Aspects Olaf Ortmann, President, German Cancer Society (presentation 30 mins, Q&A 10 mins) The German Cancer Aid Lars Jöckel, Head of Funding Department, German Cancer Aid (presentation 25 mins, Q & A 10 mins)
12:30 - 13:30	Lunch
13:30 - 15:00	Session 2: Access to Cancer Treatments Chair: Nicolas Philippou Access to Cancer Medicines in Germany Andreas Hochhaus, Board Member, German Cancer Society (presentation 30 mins, Q&A 15 mins) Let's Talk Access! ECL White Paper on Tackling Challenges in Access to Medicines ECL Access to Medicines Task Force (30min & 10 QA)
15:00 - 15:30	Coffee break
15:30 - 16:15	Session 3: Alternative treatments Chair: Roisin Foster Complementary and alternative medicine - what patients needs to know Nanna Cornelius, Danish Cancer Society (presentation 30 mins, Q&A 15 mins)
16:15- 16:30	CLOSING Sakari Karjalainen, President, Association of European Cancer Leagues

The ECL annual meetings in Berlin were a great success with many interesting sessions and opportunities for networking. ECL is grateful to the German Cancer Society for having hosted the events in Berlin and for taking very good care of the participants!

ECL Annual Meetings

Berlin, Germany, November 2018

General Assembly, 16 November 2018



38th Annual General Assembly in Berlin, kindly hosted by the German Cancer Society



ECL Patient Support Working Group

Since 2007 the ECL Patient Support Working Group (PSWG) connects cancer care experts who work together on topics such as access to insurance and financial services, return to work, caregiver support, cancer rehabilitation and palliative care. PSWG members share best practices, develop guides and other information sources to raise awareness and improve patient care. PSWG also seeks to empower the patient voice in national and European policy-making.

2018 Work Themes

- **Improved communication between patients and healthcare professionals in oncology**
Drafting a guide for patients on how they can improve communication and get all necessary information during their consultations with healthcare professionals
- **Use of volunteer services in patient support and care**
Drafting a guide for European cancer societies on how to develop and manage volunteers for the purpose of patient support
- **Return to work after cancer**
Published presentation for employers on how to handle cancer at the workplace
- **Access to insurance and the ‘right to (have a cancer) be forgotten’**
Best practice sharing on different schemes existing in France and Belgium to avoid discrimination of cancer survivors.



2018 Meetings

- 12-13 April 2018, Bucharest, Romania
- 12-13 November 2018, Berlin, Germany

New Chairmanship

On 13 November 2018, we said goodbye to our Chair Liz Atkinson from Cancer Focus Northern Ireland. Alrik Meesen from the Dutch Cancer Society was elected the new Chair and Monick Leal from the Portuguese League Against Cancer was elected the Vice-Chair for a 3-year mandate (ending in Autumn 2021).



ECL Access To Medicines Task Force

Established in 2016, the ECL Access to Medicines Task Force aims to make cancer medicines available for all cancer patients in Europe by insisting on accessibility, sustainability of the healthcare system and transparency of drug prices. The Task Force strongly believes in the power of dialogue. We urge all stakeholders to push for innovative improved treatments, improving both survival and the quality of life of cancer patients. Currently, 25 national/regional cancer societies, representing over 450 million Europeans, have signed the Task Force's Declaration of Intent.

2018 Achievements

- **Health Technology Assessment (HTA)**
 - Position paper stating cancer leagues' priorities on European cooperation on HTA
 - Toolkit for cancer societies on HTA
 - Meeting with Commissioner for Health Dr. Vytenis Andriukaitis on HTA
- **CAR-T Cell Therapies**
 - Article on pricing of CAR T-cell therapies published
 - Interview published in *Cancerworld* on CAR T-cell therapies
 - Speaking at the European Parliament on access to CAR-Ts
- **Let's Talk Access White Paper**
 - Let's Talk Access White Paper on tackling challenges in access to medicines published

- Let's Talk Access White Paper presented at the European Parliament
- Positive feedback received from policy-makers and stakeholders

- **Visibility at Conferences**

- Speeches at ECCO Summit 2018 in Vienna and UICC World Cancer Congress in Kuala Lumpur
- Dissemination of the White Paper at ESMO Congress 2018 in Munich

2018 Meetings

- 19 March 2018, Bern, Switzerland
- 14 November 2018, Berlin, Germany

Chairmanship

Eveline Scheres from the Dutch Cancer Society continued to be the Chair of the Task Force in 2018, with her mandate ending in September 2019.



MEPs Against Cancer (MAC) Parliamentary Interest Group



The MAC Group was founded in 2005 and remains the only dedicated group to cancer policy at the European Parliament. Currently there are 38 MAC members coming from all political groups and different EU Member States. The President Mr. Alojz Peterle (EPP, Slovenia), Vice-Presidents Ms. Nessa Childers (S&D, Ireland), Mr. Pavel Poc (S&D, Czech Republic), and Dr. Charles Tannock (ECR, United Kingdom), and other members are committed to taking action in the fight against cancer. The MEPs Against Cancer (MAC) work together in order to improve cancer control and prevention in Europe, in the belief that European cooperation adds value to member state actions. In order to address the challenges faced by the EU, MAC collaborate with the European Commission, the Council and other relevant organisations to reduce cancer incidence by 15% by 2020. ECL provides secretariat and knowledge support to members of the MAC Group.

2018 Meetings

- **Improving outcomes, driving efficiency in cancer care: How do we learn from best practice?** January 2018 (MEP Lieve Wierinck, Belgium)
- **Re-innovate Cancer Treatment: The Potential of Re-purposed Drugs**, February 2018 (MEPs Alojz Peterle, Slovenia and Lieve Wierinck, Belgium)
- **Quality of Cancer Care**, March 2018 (MEP Deirdre Clune, Ireland)
- **Skin Cancer: Safe Work under the Sun**, March 2018 (MEPs Marita Ulvskog, Sweden, Jens Gieseke, Germany and Alojz Peterle, Slovenia)
- **Recognising Cancer Nursing**, Mar 2018 (MEPs Alojz Peterle, Slovenia and Marian Harkin, Ireland)
- **Skin Cancer Registries in Europe: From Knowledge to Action**, June 2018 (MEPs Charles Tannock, UK and José Inácio Faria, Portugal)
- **Early Diagnosis & Cancer of Unknown Primary**, June 2018 (MEPs Theresa Griffin, UK and Christel Schaldemose, Denmark)
- **Celebrating 20 Years of Progress In Paediatric Haemato-Oncology in Europe**, September 2018 (MEPs Elena Gentile, Italy and Alojz Peterle, Slovenia)
- **Let's Talk Access – Launch of ECL's White Paper**, October 2018 (MEPs José Inácio Faria, Portugal, Tomáš Zdechovský, Czech Republic and Lieve Wierinck, Belgium)
- **Cancer, Body Weight and Healthy Diet**, October 2018 (MEP Nessa Childers, Ireland)

Tobacco Control Activities

Traceability Standards for Tobacco Products

ECL, through its Tobacco Control Advocacy Officer Luk Joossens, has been busy following the issue of traceability standards for tobacco products. Countries and regions are preparing rules for a tracking and tracing regime. In the EU, a tracking and tracing regime for cigarettes will come into force from 20 May 2019.

Big tobacco is lobbying to have an industry operated system. All major international cigarette companies support the tracking and tracing system, Codentify or Inexto, which they offer at low cost to governments. In the industry operated option, the manufacturers are responsible for the generation of the unique identifiers which they produce at the manufacturing site outside the control of governments.

In addition, in the case of the codentify, the system is not secured as the codes are visible and easy to copy or to clone. Unique identifiers are an important and essential element of any tracking and tracing system. Unique identification markings are an obligation under article 8§3 of the IPT and shall not be performed by or delegated to the industry according to article 8§12.

A tobacco industry operated system would not be option and against the obligations of the ITP. The Protocol clearly defines that the obligations of the tracking and tracing system shall not be delegated to the tobacco industry. For instance, it is stipulated in article 8 §2 that the tracking and tracing system is "controlled by the Party". In addition, it was emphasized in article 8 §13 that "each Party shall ensure that its competent authorities, in participating in the tracking and tracing regime, interact with the tobacco industry and those representing the interests of the tobacco industry only to the extent strictly necessary in the implementation of this Article."

All Parties to the FCTC had agreed (at the 7th Conference of the Parties to the WHO FCTC in India in 2016) that "Except interactions to the extent strictly necessary, parties to the Convention are urged not to consider any proposal or assistance related to tracking and tracing from the tobacco industry or submitted on their behalf, including in the course of the preparatory activities for MOP1 in accordance with their obligation under WHO FCTC."

Cancer Prevention

The European Code Against Cancer (ECAC) is an initiative of the European Commission to inform people about actions they can take for themselves or their families to reduce their risk of cancer. ECAC is comprised of 12 evidence-based recommendations, which the public can understand and follow without any special skills or advice.

Following the publication of the 4th edition of the ECAC, the Association of European Cancer Leagues (ECL) received the mandate from the European Commission to disseminate the ECAC by encouraging close cooperation with cancer leagues at the national and regional level.

In 2018, ECL built on the preceding years' activities in continuing to promote the messages of the European Code against Cancer as the essential tool for cancer prevention in Europe. In addition, despite the long-term commitment to the promotion of the ECAC by the cancer prevention community in the years since its initial launch, no systematic evaluation of the impact of ECAC has been undertaken. To address this gap, ECL has worked with the International Agency for Research on Cancer (IARC) to develop an evaluation framework of the ECAC, which will be implemented in the coming year.

Key Activities

ECL YOUTH AMBASSADORS FOR THE ECAC

- 72 actions were performed either individually or as a group across the year in their respective countries;
- The Youth Ambassadors group enjoyed a dramatic increase with the group membership doubling in size. By the end of 2018, the group comprised 42 ambassadors from 34 countries;
- The highlight of the Youth Ambassadors programme in 2018 was the successful summer school hosted by La Ligue contre le Cancer in

Paris. 34 Ambassadors took part in the summer school which provided direct training for the ambassadors on effective methods for promoting ECAC and drafted the strategy of the group for the next 12 months;

- A social media toolkit aimed specifically at the Youth Ambassadors was developed;



EUROPEAN CODE AGAINST CANCER (ECAC) MEETINGS

- The first meeting of the expert advisory group in Brussels in February 2018 to brainstorm the framework to evaluate the impact of the ECAC. This involved 8 members of the scientific working groups formed during the drafting of the 4th edition of the ECAC;
- ECL collected an overview of ECAC actions undertaken by the leagues and started a process of short interviews with cancer leagues to appreciate barriers and supportive factors for the promotion and adoption of ECAC;
- The annual ECAC workshop for cancer leagues took place at IARC in Lyon with the representation of 8 cancer leagues.
- The ECL sun and uv safety recommendations were updated in April 2018 following survey of sun safety contacts and external experts. The recommendations were updated following

Cancer Prevention

debate with cancer leagues and experts as a side meeting of the Euroskin conference;

- A roundtable to promote the consumption of wholegrain foods consistent with the ECAC message on health diets. The Danish Wholegrain Partnership as submitted as a best practice example to the steering group on health promotion and disease prevention with the aim of facilitating the adaptation of the partnership model to other countries.

EU PROJECTS: MYPEBS & WASABY

In 2018 ECL started work on two exciting new project: MyPeBS (personalising breast screening) and WASABY (developing an innovative health promotion tool for school age girls).



MyPeBS

- MyPeBS is based on a large international clinical study that compares current screening with a new personalised screening approach based on estimating the individual risk of developing breast cancer in the coming years. This new strategy proposes to adapt the screening schedule to each woman's individual risk.
- Women who volunteer to participate in the study are randomly assigned to two groups. In the first, they follow the standard screening during the 4 years of participation in the study; in the second,

they follow their personalised screening schedule, established according to their own risk of developing breast cancer.

- ECL is directly involved in work package 6 (communication), leading the specific task to communicate the project to the general public, and will also contribute to the work packages assessing psychosocial impact of risk-stratification and recommendations for policy-makers.
- In 2018 ECL led on the stakeholder mapping and design of initial communication materials to the public to introduce and explain the project.



WASABY

- WASABY is a 3-year pilot programme funded through the EU Health Programme, beginning in January 2018. The action focuses on the geographical analysis of population-based cancer incidence data in connection with environmental factors, using breast cancer and water/soil contamination as an example.
- The Association of European Cancer Leagues (ECL) is responsible for dissemination, including developing the primary prevention tool to promote cancer prevention to school age females.
- In 2018, ECL developed the first promotional materials for the project, including the design of the visual identity, and conducted a comprehensive stakeholder mapping exercise.





THE ECL SECRETARIAT

ECL Secretariat Activities Secretariat activities are planned and implemented in line with ECL Strategic Goals as part of the ECL Strategy 2014-2018. The new strategy for 2019-2021 was developed and approved by the General Assembly in Berlin. In line with the previous strategy, ECL STRATEGIC GOALS for the next 3 years aim at ensuring that that promotion of cancer research - addressing inequalities in Europe, access to high quality cancer treatment and care, and enhanced patient involvement in healthcare - is regarded in all of ECL's activities and advocacy. ECL represents its member societies and is independent of external influence.

This year, 2018, is the first of the three years of the new Operating Grant period. Final approval was granted in May 2018.

The vision of Association of European Cancer Leagues (ECL) is for a Europe Free of Cancers. The role of ECL is to facilitate the collaboration between cancer leagues throughout Europe and to influence EU and pan-European policies. The mission of the Association of European Cancer Leagues is to influence and improve cancer control and cancer care in Europe through collaboration between its members in their fight against cancer, and to influence EU and pan-European policies.

The ECL Secretariat works on activities in line with the ECL's Strategic Goals.

In addition to above-mentioned areas of work, selected activities are highlighted below for the Strategic Goals.

Goal 1: Influence cancer control policies

- Providing the Secretariat to the MAC (Members of the European Parliament (MEPs) Against Cancer) group, and organizes roundtables for MEPs, often in collaboration with relevant organisations.

- In EU Joint Actions as subcontractors, ECL is involved in
 - Joint Action on Innovative Partnership Action Against Cancer (www.ipaac.eu) - with Finland
 - Joint Action on Vaccinations - with France
- Meeting with EU Commissioner and other officials on Tobacco Control, HTA, Diet, Physical Activity and Health, Sunbeds
- ECL is a partner in EU funded projects (MyPeBS, WASABY)
- ECL is active in the EU Health Policy Forum, EU Platform on Diet, Physical Activity and Health

Goal 2: Promote cancer prevention

- Promotion of the European Code against Cancer (www.cancercode.eu)
- Code Evaluation Experts meetings with WHO's International Agency for Research on Cancer (IARC)
- Participate and support league meetings on Code
- MAC meetings on occupational skin cancer, alcohol, healthy body weight
- Present on ECL Code Activities to Member States at EU Platform on Diet, Physical Activity and Health
- Met with EU officials on next steps on EU Sunbeds Scientific Opinion
- Coordinated ECL Prevention Youth Ambassadors activities at national and European level e.g., Youth Ambassadors Summer School
- Engaged in tobacco control activities at European and global level
- Active in European Conference on Tobacco or Health (ECToH) 2020 planning with German Cancer Society www.ectoh.org

THE ECL SECRETARIAT

Goal 3: Encourage access to cancer screening

- Participate as subcontractor in EU Joint Action on Innovative Partnership Action Against Cancer (www.ipaac.eu), with Finland
- Dissemination partner in EU-funded MyPeBS (My Personal Breast Screening) research project

Goal 4: Ensure access to treatment and support

- Access to Medicines Task Force
- Patient Support Working Group

Goal 5: Support the development and implementation of national cancer control programmes and cancer registries

- MEPs Against Cancer meeting on cancer registries
- Monitor EU Joint Action iPAAC work package on updated analysis of national cancer control plans

The ECL Secretariat was staffed by the following in 2018:

Wendy Yared	Director
David Ritchie	Senior Cancer Control Officer
Anna Prokupkova	Policy and Project Officer
Ghislaine Gerbier	Administrative Coordinator, until end of June 2018
Elisabeth Dupont	Operations Coordinator, since June 2018
Luk Joossens	Tobacco Control Advocacy Officer

The following Solidarity Corps trainees were also part of the Secretariat in 2018:

Asnate Kaupe - February - July 2018

Meritxell Mallafré Larrosa - September - December 2018





ECL MEMBERS

BELGIUM

Foundation Against Cancer

Fondation contre le Cancer
Chaussée de Louvain 479, 1030 Brussels
Tel: +32 2 736 99 99
Website: www.cancer.be
E-mail: info@cancer.be



CZECH REPUBLIC

League Against Cancer Prague

Liga Proti Rakovině Praha
Na Truhláře 100/60, CZ-180 81 Prague
Tel: +420 224 919 732
Website: www.lpr.cz
E-mail: lpr@lpr.cz



Stand Up to Cancer (Flanders)

Kom Op Tegen Kanker
Tel: +32 2 227 69 69
Koningsstraat 217, 1210 Brussels
Website: www.komoptegenkanker.be
E-mail: info@komoptegenkanker.be



DENMARK

Danish Cancer Society

Kræftens Bekæmpelse
Strandboulevarden 49, DK-2100 Copenhagen
Tel: +45 35 25 75 00
Website: www.cancer.dk
E-mail: info@cancer.dk, eh@cancer.dk



CATALONIA

Catalan Federation of Entities against Cancer (FECEC)

Hotel d'Entitats La Pau,
C/Pere Vergés, 1 11a planta
08020 Barcelona
Tel: +34 93 314 87 53
E-mail: gerencia@juntscontraelcancer.cat
Website: www.juntscontraelcancer.cat/en/



FAROE ISLANDS

The Faroese Cancer Society

Føroya Felag Móti Krabbameini
Grønlandsvegur 58, P.O. Box 1216,
FO-100 Tórshavn
Tel: +298 317 959
Website: www.krabbamein.fo
E-mail: ffk@post.olivant.fo



CYPRUS

The Cyprus Association of Cancer Patients and Friends

12-14 Photinou Pana Street, 1045 Nicosia
P.O. Box 23868, CY-1687 Nicosia, Cyprus
Tel: +357 22 345 444
Website: www.cancercare.org.cy
E-mail: caocpat@cvtanet.com.cy



FINLAND

Cancer Society of Finland

Unioninkatu 22
00130 Helsinki, Finland
Tel: +358 9 135 3310
Website: www.cancer.fi
E-mail: tiedotus@cancer.fi, Sakari.Karjalainen@cancer.fi



The Cyprus Anti-Cancer Society

Paraskeva Ioannou 2
CY-2420 Strovolos
Tel: +357 22 497 373
Website: www.anticancersociety.org.cy
E-mail: vassilis.i@anticancersociety.org.cy



FRANCE

French Cancer League

Ligue contre le Cancer
14, rue Corvisart
75013 Paris
Tel: +33 1 53 55 28 89
www.ligue-cancer.net



ECL MEMBERS

GERMANY

German Cancer Society

Deutsche Krebsgesellschaft e. V.
Kuno-Fischer-Str. 8 | 14057 Berlin
Tel. +49 030 – 322 932 970
helbig@krebsgesellschaft.de
www.krebsgesellschaft.de



LUXEMBURG

Luxembourgish Foundation against Cancer Fondation Cancer

209, route d'Arlon, L-1150 Luxembourg
Tel: +352 45 30 331
Website: www.cancer.lu
E-mail: fondation@cancer.lu



HUNGARY

Hungarian League Against Cancer

Magyar Rakellenes Liga
P.O. Box 7, 1507 Budapest, Hungary
Tel: +36 1 202 4017
Website: www.rakliga.hu
E-mail: info@rakliga.hu



THE NETHERLANDS

Dutch Cancer Society

KWF Kankerbestrijding
Delflandlaan 17
NL 1070 AM Amsterdam
Tel: +31 (020) 570 05 50
Website: www.kwfkankerbestrijding.nl
E-mail: info@kwf.nl



ICELAND

Icelandic Cancer Society

Krabbameinsfélagið
Skogarhlid 8 P.O. Box 5420, IS-125 Reykjavik
Tel: +354 540 1900
Website: www.krabb.is
E-mail: inga@krabb.is



POLAND

Polish Cancer League

ul. Nowolipki 9 b
00-151 Warszawa
Tel. +48 793 493 893
biuro@ligawalkizrakiem.pl
http://www.ligawalkizrakiem.pl/



IRELAND

Irish Cancer Society

5 Northumberland Road, Dublin 4, Ireland
Tel: +351 1 231 0500
Website: www.cancer.ie
E-mail: reception@cancer.ie,
jmccormack@irishcancer.ie



PORTUGAL

Portuguese Cancer League

Liga Portuguesa contra o Cancro
Av. Columbano Bordalo Pinheiro, 57-3F
1070-061 Lisboa, Portugal
Tel: +351 21 722 1810
Website: www.ligacontracancro.pt
E-mail: info@ligacontracancro.pt



ISRAEL

Israel Cancer Association

Bei Mati
7 Revivim Street, 53103 Givatayim, Israel
Tel: +972 3 572 16 16
Website: www.cancer.org.il
E-mail: noemier@cancer.org.il



ROMANIA

Romanian Cancer Society

Societatea Romana de Cancer
str. Bisericii Ortodoxe nr. 11
400090 Cluj-Napoca
Tel/fax: +40 264 450 095
Website: www.srcorg.ro/
E-mail: office@srcorg.ro





ECL MEMBERS

ITALY

Italian Cancer League

Lega Italiana per la Lotta contro i Tumori

Via Torlonia, 15, I-00161 Rome

Tel: +39 06 44 25 971

Website: www.legatumori.it

E-mail: sede.centrale@lilt.it



SLOVAKIA

League Against Cancer Slovakia

Liga proti rakovine SR

Brestova 6, 821 02 Bratislava, Slovakia

Tel: +421 2 5292 1735

Website: www.lpr.sk

E-mail: lpr@lpr.sk



SLOVENIA

Association of Slovenian Cancer Societies

Zveza slovenskih društev za boj proti raku

Zaloska Cesta 2, 1001 Ljubljana, Slovenia

Tel: 386 01 4309 780

E-mail: MZakelj@onko-i.si



TURKEY

Turkish Association for Cancer Research and Control

Türk Kanser Araştırma Ve Savaş Kurumu

Atac sokak No:21/1, 06410 Yenisehir-Ankara, Turkey

Tel: +90-312-431 2950

Website: www.turkkanser.org.tr

E-mail: info@turkkanser.org.tr,

tkutluk@gmail.com



SWITZERLAND

Swiss Cancer League

Krebsliga Schweiz

Effingerstrasse 40, Postfach 8219,

CH-3001 Berne, Switzerland

Tel: +41 31 389 91 10

Website: www.swisscancer.ch

E-mail: info@liguecancer.ch,

kathrin.kramis@krebssliga.ch



UNITED KINGDOM

Cancer Focus Northern Ireland

40-42 Eglantine Avenue,

BT9 6DX Belfast, Northern Ireland

Tel: +44 (0)28 9066 3281

Website: www.cancerfocusni.org

E-mail: hello@cancerfocusni.org



FINANCIAL REPORT

European Cancer Leagues ASBL Chaussée de Louvain 479 1030 Brussels

BALANCE SHEET AS OF DECEMBER 31, 2018



ASSETS

FIXED ASSET

Website	8.396,70	
Depreciation	-4.197,81	
Furniture	8.021,84	
Depreciation	-6.224,42	
		5.996,31

AMOUNTS RECEIVABLE WITHIN ONE YEAR

Receivables	48.805,00	
Other receivables	0,00	
		48.805,00

CASH AT BANK AND IN HAND

BNP Paribas Fortis Bank	640.996,87	
Business depo	13,34	
Pretty cash	98,19	
		641.108,40

DEFERRED CHARGES AND ACCRUED INCOME

Prepaid expenses	25.120,77	
Accrued revenues	90.869,10	
		115.989,87

TOTAL ASSETS

811.899,58



LIABILITIES

SOCIAL FUND OF THE ASSOCIATION

Social fund	37.110,00	
		37.110,00

RESERVES

Social liability	211.000,00	
		211.000,00

ACCUMULATED RESULT

Revenues in excess of expenses	164.306,95	
		164.306,95

AMOUNTS PAYABLE WITHIN ONE YEAR

Suppliers and invoices to be received	41.384,13	
Taxes to be paid	19.064,11	
Salaries and social security to be paid	36.660,67	
		97.108,9

ACCRUED CHARGES AND DEFERRED INCOME

Deferred income	302.373,72	
		302.373,72

TOTAL LIABILITIES

811.899,58





FINANCIAL REPORT

European Cancer Leagues ASBL Chaussée de Louvain 479 1030 Brussels

P&L ACCOUNT AS OF DECEMBER 31,2018



OPERATING INCOME AND CHARGES

Turnover : Membership fees	182.165,90
Sponsoring	47.000,00
Grant EC	302.894,79
Other income	22.185,44
Total income	554.246,13
Services and other goods	-221.207,65
Remuneration and social security costs	-319.989,34
Depreciation	-4.263,99
Operating profit	8.785,15

FINANCIAL INCOME AND CHARGES

Financial income	130,25
Financial charges	-389,37
Current profit of the year	8.526,03

EXTRAORDINARY INCOMES AND CHARGES

Extraordinary incomes	0,00
Extraordinary charges	0,00
Withholding tax on financial income	0,00

REVENUES IN EXCESS OF EXPENSES	8.526,03
---------------------------------------	-----------------

FINANCIAL REPORT



Registered Auditors

Kortemansstraat 2a - B-1731 Zellik

Association of European Cancer Leagues ASBL
Chaussée de Louvain 479
1030 Brussels

AUDITOR'S REPORT FOR THE FINANCIAL YEAR STARTED ON THE 1ST JANUARY 2018 AND ENDED ON THE 31ST DECEMBER 2018 OF THE ASSOCIATION OF EUROPEAN CANCER LEAGES (ECL) (RPR 0867.170.595)

Objective and scope of the review

Upon the request of the Director, we have reviewed the accompanying financial statements of the ASSOCIATION OF EUROPEAN CANCER LEAGES (ECL) as at December 31st, 2018. The Board of Directors of ECL is responsible for the preparation of this financial information in accordance with the Belgian generally accepted accounting principles. These statements indicate a balance sheet total of € 811.899,58 as well as revenues in excess of expenses of € 8.526,03.

We conducted our review in accordance with the legal requirements and the Auditing Standards applicable in Belgium, as issued by the Institute of Registered Auditors (*Institut des Réviseurs d'Entreprises / Instituut van de Bedrijfsrevisoren*) and, more particularly, in accordance with its Standards in regards to a limited review.

This review, in accordance with the aforementioned standards, consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters.

A limited review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements. Accordingly, we do not express an audit opinion. A limited review does not provide assurance that we would become aware of any or all significant matters that might be identified in an audit.

Review

We have obtained from the management and responsible officers of the Association all of the explanations and information necessary for our review. We believe that the evidence we have obtained in our review is sufficient and appropriate to provide a basis for our conclusion.

In our opinion, the financial statements as of December 31st, 2018, were established in accordance with the financial reporting framework applicable in Belgium and the accounting records were maintained with the legal and regulatory requirements applicable in Belgium.





FINANCIAL REPORT



2

The current revenues amount to € 554.376,38 and the expenses amount to € 545.850,35 and hence, the financial statement as at 31st December 2018 indicates revenues in excess of expenses of € 8.526,03.

After thorough examination and analysis of the available documents and data, we can confirm that operating costs were sufficiently justified by supporting documents.

Additional information

The compliance by the Association with the law of 27 June 1921 related to not-for-profit associations, international not-for-profit associations and Associations is the responsibility of management.

Without prejudice to formal aspects of minor importance, the accounting records were maintained in accordance with the legal and regulatory requirements applicable in Belgium.

There are no transactions undertaken or decisions taken in violation of the Associations by-laws or the law of 27 June 1921 related to not-for-profit associations, international not-for-profit associations and Associations that we have to report to you.

Conclusion

We have reviewed the accompanying financial statements of the ASSOCIATION OF EUROPEAN CANCER LEAGES (ECL) as at 31st of December 2018, prepared by its Board of Directors, indicating a balance sheet total of € 811.899,58 and revenues in excess of expenses of € 8.526,03.

Based on our reviews, nothing has come to our attention that causes us to believe that the financial statements are not prepared, in all material respect, in accordance with the Belgian generally accepted accounting principles.

Zellik, 5th of March 2019

Luteijn, Serghini & Co Registered Auditors BVBA
represented by Saskia Luteijn

MEMBERSHIP OVERVIEW FOR 2018



www.cancer.eu



@cancerleagues



@cancerleagues





MEMBERSHIP OVERVIEW FOR 2018

Foundation Against Cancer Belgium
Stand Up To Cancer Flanders
Cyprus Anti-Cancer Society
Cyprus Association of Cancer Patients and Friends
League Against Cancer Prague
Danish Cancer Society
Faroese Cancer Society
Cancer Society of Finland
French League Against Cancer
German Cancer Society
Hungarian League Against Cancer
Icelandic Cancer Society
Irish Cancer Society
Israel Cancer Association
Italian Cancer League
Cancer Foundation Luxembourg
Dutch Cancer Society
Polish Cancer League
Portuguese League Against Cancer
Romanian Cancer Society
League Against Cancer Slovakia
Association of Slovenian Cancer Societies
Swiss Cancer League
Catalan Federation Against Cancer
Turkish Association for Cancer Research and Control
Cancer Focus Northern Ireland